Developer docs
API playgroundTry for free, no card

Search company profiles

Validus Pharmaceuticals

Full company profile

uuid0007mgy

Namestring
Validus Pharmaceuticals
Legal namestring
Validus Pharmaceuticals LLC
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Validus Pharmaceuticals LLC is a privately held U.S. specialty pharmaceutical company headquartered in Parsippany, New Jersey (90 East Halsey Road, Suite 210), founded in 2007 and operating with 11–50 employees. Rather than developing new chemical entities, the company acquires, reformulates, and markets established FDA-approved prescription products that address unmet clinical needs in specialty therapeutic areas. Its current portfolio consists of five acquired brands: Equetro (bipolar disorder), Raldesy (specialty therapeutic area), Lopressor (hypertension, beta-blocker), Lasix (loop diuretic for fluid retention/edema), and Lotensin HCT (combination antihypertensive). The company serves U.S. healthcare providers and patients through standard pharmaceutical distribution channels and a Patient Assistance Program for eligible patients.

Validus's revenue model is product commercialization of prescription pharmaceuticals, supplemented by licensing partnerships for established brands. Pricing is not publicly disclosed—consistent with prescription pharmaceutical norms where prices are negotiated through PBMs, payers, and providers—and the company operates a Comprehensive Compliance Program aligned with the PhRMA Code and HHS-OIG guidance, including formal policies on HCP detailing, samples management, and fraud-and-abuse training. Its go-to-market is enterprise field sales: healthcare-professional detailing supplemented by direct engagement with the medical community, a Patient Assistance Program for patient pull-through, and an explicit channel for business-development executives to propose licensing partnerships. The company is registered as an LLC in New Jersey, has no parent company, and shows no evidence of institutional or venture backing.

Operationally, Validus is a small, focused commercial-stage specialty pharma whose core differentiator is brand stewardship rather than R&D. Leadership includes CEO John Kinney and COO Emile Williams, the latter bringing 20+ years of commercial and finance experience from Shionogi, Novartis Pharmaceuticals, and Hoffmann-La Roche. The company markets exclusively in the United States, maintains state-level WAC pricing disclosures (Colorado, Connecticut for Raldesy), and is actively soliciting licensing partnerships, signaling a strategy of portfolio breadth through in-licensing rather than organic development or geographic expansion.

Short descriptiontext

Validus Pharmaceuticals LLC acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. The company commercializes five brands—Equetro, Raldesy, Lopressor, Lasix, and Lotensin HCT—through US pharmaceutical distribution, serving healthcare providers and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, prescription drug marketing, product reformulation, FDA-approved medications, pharmaceutical licensing
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Commercialization
TypeOne Time License
Description

Validus generates revenue through the acquisition, reformulation, and commercialization of FDA-approved prescription products in specialty therapeutic areas. The company also derives value through licensing partnerships where they bring established brands to market.

validuspharma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Marketing or Sales, Supply Chain, Personnel, Operations, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Equetro
Description

Prescription pharmaceutical product marketed by Validus Pharmaceuticals

validuspharma.com
+4 more records
Core offering1 text field

Validus Pharmaceuticals acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. Its portfolio includes Equetro for bipolar disorder, Raldesy (specialty therapeutic area), Lopressor (hypertension), Lasix (fluid retention/edema), and Lotensin HCT (combination antihypertensive). The company also pursues licensing partnerships with business development executives to extend the value of established brands.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Validus Pharmaceuticals LLC is a specialty pharmaceutical company focused on acquiring, reformulating, and marketing FDA-approved prescription products that address unmet clinical needs. The company's portfolio consists of five acquired brands spanning multiple therapeutic areas: Equetro (bipolar disorder treatment), Raldesy (specialty therapeutic area), Lopressor (cardiovascular/hypertension), Lasix (diuretic for fluid retention), and Lotensin HCT (combination antihypertensive). Rather than developing new products, Validus acquires established products and commercializes them through its distribution and partnership network.

Product and service5 records
1Equetro
CategoryAcquired brand
Description

A prescription medication for the treatment of bipolar disorder, acquired and commercialized by Validus Pharmaceuticals.

2Raldesy
CategoryAcquired brand
Description

A prescription pharmaceutical product acquired and marketed by Validus Pharmaceuticals in specialty therapeutic areas.

3Lopressor
CategoryAcquired brand
Description

A beta-blocker medication for the treatment of hypertension, acquired and commercialized by Validus Pharmaceuticals.

4Lasix
CategoryAcquired brand
Description

A loop diuretic medication for the treatment of fluid retention and edema, acquired and commercialized by Validus Pharmaceuticals.

5Lotensin HCT
CategoryAcquired brand
Description

A combination medication for the treatment of hypertension, acquired and commercialized by Validus Pharmaceuticals.

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Validus Pharmaceuticals welcomes inquiries from business development executives interested in licensing partnerships. The company focuses on deriving further value from established brands through partnerships. The company is open to acquiring and commercializing prescription products that satisfy unmet clinical needs in specialty therapeutic areas.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vertically integrated pharmaceutical company with significant branded and generic prescription product offerings across cardiovascular and CNS. Comparable to Validus in commercial portfolio strategy, though much larger in manufacturing and scale.

TypeDirect peer
Description

Private specialty pharmaceutical company marketing established branded prescription products, including cardiovascular and CNS franchises. Comparable to Validus in business model (acquire and commercialize legacy brands) and approximate scale.

TypeDirect peer
Description

Specialty and generic pharmaceutical company focused on affordable prescription medicines across therapeutic categories. Comparable to Validus in operating a multi-brand prescription portfolio with both legacy and specialty assets.

TypeDirect peer
Description

Privately held pharmaceutical company developing, manufacturing, and marketing a broad range of generic and specialty prescription medicines. Comparable to Validus in private ownership and multi-therapeutic prescription portfolio approach.

TypeDirect peer
Description

Specialty and generic pharmaceutical company marketing branded and generic prescription products, including cardiovascular and CNS franchises. Directly comparable to Validus in commercial model and therapeutic mix.

TypeDirect peer
Description

Specialty pharma focused on acquiring, developing, and commercializing branded and generic prescription products in niche therapeutic areas. Closely comparable to Validus in scale, acquisition-led strategy, and focus on established molecules.

TypeDirect peer
Description

Specialty pharma company with a portfolio of branded and generic prescription products across multiple therapeutic areas. Comparable in the brand-acquisition and lifecycle-extension approach, though larger in scale.

TypeBroad incumbent
Description

Large diversified specialty pharmaceutical company with a broad branded prescription portfolio across multiple therapeutic areas. Comparable to Validus in brand-acquisition strategy, but operates at significantly greater scale across many categories.

TypeDirect peer
Description

Specialty pharmaceutical company that acquires, develops, and markets branded prescription products across multiple therapeutic areas. Directly comparable to Validus in its brand-acquisition and lifecycle-management model, including exposure to mature cardiovascular and CNS franchises.

TypeDirect peer
Description

Privately held specialty pharmaceutical company that markets authorized generics and branded prescription products. Comparable to Validus in leveraging established molecules and brand recognition in commercial markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Validus Pharmaceuticals

Specialty Pharmaceuticalsvaliduspharma.com

Validus Pharmaceuticals LLC acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. The company commercializes five brands—Equetro, Raldesy, Lopressor, Lasix, and Lotensin HCT—through US pharmaceutical distribution, serving healthcare providers and patients.

What Validus Pharmaceuticals does

Validus Pharmaceuticals LLC is a privately held U.S. specialty pharmaceutical company headquartered in Parsippany, New Jersey (90 East Halsey Road, Suite 210), founded in 2007 and operating with 11–50 employees. Rather than developing new chemical entities, the company acquires, reformulates, and markets established FDA-approved prescription products that address unmet clinical needs in specialty therapeutic areas. Its current portfolio consists of five acquired brands: Equetro (bipolar disorder), Raldesy (specialty therapeutic area), Lopressor (hypertension, beta-blocker), Lasix (loop diuretic for fluid retention/edema), and Lotensin HCT (combination antihypertensive). The company serves U.S. healthcare providers and patients through standard pharmaceutical distribution channels and a Patient Assistance Program for eligible patients.

Validus's revenue model is product commercialization of prescription pharmaceuticals, supplemented by licensing partnerships for established brands. Pricing is not publicly disclosed—consistent with prescription pharmaceutical norms where prices are negotiated through PBMs, payers, and providers—and the company operates a Comprehensive Compliance Program aligned with the PhRMA Code and HHS-OIG guidance, including formal policies on HCP detailing, samples management, and fraud-and-abuse training. Its go-to-market is enterprise field sales: healthcare-professional detailing supplemented by direct engagement with the medical community, a Patient Assistance Program for patient pull-through, and an explicit channel for business-development executives to propose licensing partnerships. The company is registered as an LLC in New Jersey, has no parent company, and shows no evidence of institutional or venture backing.

Operationally, Validus is a small, focused commercial-stage specialty pharma whose core differentiator is brand stewardship rather than R&D. Leadership includes CEO John Kinney and COO Emile Williams, the latter bringing 20+ years of commercial and finance experience from Shionogi, Novartis Pharmaceuticals, and Hoffmann-La Roche. The company markets exclusively in the United States, maintains state-level WAC pricing disclosures (Colorado, Connecticut for Raldesy), and is actively soliciting licensing partnerships, signaling a strategy of portfolio breadth through in-licensing rather than organic development or geographic expansion.

Validus Pharmaceuticals firmographics

Firmographics
Name
Validus Pharmaceuticals
Legal name
Validus Pharmaceuticals LLC
Website
https://validuspharma.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Validus Pharmaceuticals LLC acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. The company commercializes five brands—Equetro, Raldesy, Lopressor, Lasix, and Lotensin HCT—through US pharmaceutical distribution, serving healthcare providers and patients.
Ownership category
akta.pro rank

Validus Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Prescription drug marketing
  • Product reformulation
  • FDA-approved medications
  • Pharmaceutical licensing

Where Validus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Validus Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Marketing or Sales, Supply Chain, Personnel, Operations, Technology or R&D, Others

Revenue model

  1. Product Commercialization: Validus generates revenue through the acquisition, reformulation, and commercialization of FDA-approved prescription products in specialty therapeutic areas. The company also derives value through licensing partnerships where they bring established brands to market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Validus Pharmaceuticals product offering

Product offering

Core offering

Validus Pharmaceuticals acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. Its portfolio includes Equetro for bipolar disorder, Raldesy (specialty therapeutic area), Lopressor (hypertension), Lasix (fluid retention/edema), and Lotensin HCT (combination antihypertensive). The company also pursues licensing partnerships with business development executives to extend the value of established brands.

Product overview

Validus Pharmaceuticals LLC is a specialty pharmaceutical company focused on acquiring, reformulating, and marketing FDA-approved prescription products that address unmet clinical needs. The company's portfolio consists of five acquired brands spanning multiple therapeutic areas: Equetro (bipolar disorder treatment), Raldesy (specialty therapeutic area), Lopressor (cardiovascular/hypertension), Lasix (diuretic for fluid retention), and Lotensin HCT (combination antihypertensive). Rather than developing new products, Validus acquires established products and commercializes them through its distribution and partnership network.

Differentiator

Problem solved

Functional benefit

Brands

  • Equetro: Prescription pharmaceutical product marketed by Validus Pharmaceuticals
  • Raldesy
  • Lopressor
  • Lasix
  • Lotensin HCT

Products and services

  • Equetro A prescription medication for the treatment of bipolar disorder, acquired and commercialized by Validus Pharmaceuticals.
  • Raldesy A prescription pharmaceutical product acquired and marketed by Validus Pharmaceuticals in specialty therapeutic areas.
  • Lopressor A beta-blocker medication for the treatment of hypertension, acquired and commercialized by Validus Pharmaceuticals.
  • Lasix A loop diuretic medication for the treatment of fluid retention and edema, acquired and commercialized by Validus Pharmaceuticals.
  • Lotensin HCT A combination medication for the treatment of hypertension, acquired and commercialized by Validus Pharmaceuticals.

Companies that use Validus Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

Validus Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Validus Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Licensing Partnership CandidatescoreChannel Partner/ Reseller/ DistributorValidus Pharmaceuticals welcomes inquiries from business development executives interested in licensing partnerships. The company focuses on deriving further value from established brands through partnerships. The company is open to acquiring and commercializing prescription products that satisfy unmet clinical needs in specialty therapeutic areas.

Recent moves5 records

Expansion highlights4 records

Validus Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Aurobindo Pharma: Vertically integrated pharmaceutical company with significant branded and generic prescription product offerings across cardiovascular and CNS. Comparable to Validus in commercial portfolio strategy, though much larger in manufacturing and scale.
  • Upsher-Smith Laboratories: Private specialty pharmaceutical company marketing established branded prescription products, including cardiovascular and CNS franchises. Comparable to Validus in business model (acquire and commercialize legacy brands) and approximate scale.
  • Amneal Pharmaceuticals: Specialty and generic pharmaceutical company focused on affordable prescription medicines across therapeutic categories. Comparable to Validus in operating a multi-brand prescription portfolio with both legacy and specialty assets.
  • Apotex: Privately held pharmaceutical company developing, manufacturing, and marketing a broad range of generic and specialty prescription medicines. Comparable to Validus in private ownership and multi-therapeutic prescription portfolio approach.
  • Hikma Pharmaceuticals: Specialty and generic pharmaceutical company marketing branded and generic prescription products, including cardiovascular and CNS franchises. Directly comparable to Validus in commercial model and therapeutic mix.
  • ANI Pharmaceuticals: Specialty pharma focused on acquiring, developing, and commercializing branded and generic prescription products in niche therapeutic areas. Closely comparable to Validus in scale, acquisition-led strategy, and focus on established molecules.
  • Mallinckrodt Pharmaceuticals: Specialty pharma company with a portfolio of branded and generic prescription products across multiple therapeutic areas. Comparable in the brand-acquisition and lifecycle-extension approach, though larger in scale.
  • Endo Pharmaceuticals: Specialty pharmaceutical company that acquires, develops, and markets branded prescription products across multiple therapeutic areas. Directly comparable to Validus in its brand-acquisition and lifecycle-management model, including exposure to mature cardiovascular and CNS franchises.
  • Prasco Laboratories: Privately held specialty pharmaceutical company that markets authorized generics and branded prescription products. Comparable to Validus in leveraging established molecules and brand recognition in commercial markets.

Broad incumbents

  • Bausch Health: Large diversified specialty pharmaceutical company with a broad branded prescription portfolio across multiple therapeutic areas. Comparable to Validus in brand-acquisition strategy, but operates at significantly greater scale across many categories.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Validus Pharmaceuticals social profiles

Digital presence

Validus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Validus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Validus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Validus Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Validus Pharmaceuticals

What does Validus Pharmaceuticals do?

Validus Pharmaceuticals acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. Its portfolio includes Equetro for bipolar disorder, Raldesy (specialty therapeutic area), Lopressor (hypertension), Lasix (fluid retention/edema), and Lotensin HCT (combination antihypertensive). The company also pursues licensing partnerships with business development executives to extend the value of established brands.

Is Validus Pharmaceuticals a public or private company?

Validus Pharmaceuticals is a private company. It is classified as unknown and is currently operating.

When was Validus Pharmaceuticals founded?

Validus Pharmaceuticals was founded in 2007. It employs 11 to 50 people.

Where is Validus Pharmaceuticals based?

Validus Pharmaceuticals is headquartered in Parsippany, United States, in the North America region.

How does Validus Pharmaceuticals make money?

One revenue line is on record: product Commercialization.

Who are Validus Pharmaceuticals's main competitors?

Direct peers on record are Aurobindo Pharma, Upsher-Smith Laboratories, Amneal Pharmaceuticals, Apotex, Hikma Pharmaceuticals, ANI Pharmaceuticals, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals and Prasco Laboratories. Bausch Health is listed as a broad incumbent.

Does Validus Pharmaceuticals have an API?

No public API is recorded for Validus Pharmaceuticals.

What industry is Validus Pharmaceuticals in?

Validus Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals